Brugia pahangi in the BALB/C mouse: a model for testing filaricidal compounds.
The BALB/C mouse infected with Brugia pahangi has been evaluated as a model for the selection of filaricidal compounds with activity against immature worms. Mice were infected by the intraperitoneal inoculation of 50 infective larvae and candidate compounds were administered by the intraperitoneal (i.p.), subcutaneous or oral route once daily from day 4 to day 8 post infection. Animals were examined on days 29 to 32 post infection. Variation in the larval recoveries from undrugged mice within and between experimental groups limited the value of drug assessments based upon percentage worm recoveries. The infection rate of undrugged mice was 85% over-all, range 60 to 100%. Using the infection rate of drugged v. undrugged animals as the criterion of activity the test has been evaluated with a series of standard nematicidal compounds. Levamisole and the benzimidazole carbamates, mebendazole, flubendazole and fenbendazole given i.p. at 10 mg/kg daily were active in this screen whilst DEC, DEC-N-oxide, ivermectin, amoscanate, metrifonate and suramin were inactive at the dosages tested. No retardation of growth or morphological abnormalities were observed in worms from the drugged mice.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002009:Brugia; D004195:Disease Models, Animal; D004605:Elephantiasis, Filarial / Q000188:drug therapy*; D005369:Filaricides / Q000627:therapeutic use*; D008209:Lymphedema / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C
D000871:Anthelmintics; D005369:Filaricides